Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 8/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25943367 | 0.78 | CNR2 (0.43) | DRD3GPR119 | |
| SCHEMBL19251290 | 0.75 | CNR2 (0.46) | — | |
| SCHEMBL27064600 | 0.74 | CNR2 (0.41) | GPR119 | |
| SCHEMBL10086343 | 0.74 | DRD2 (0.46) | PDE10ADRD2DRD4DRD3KDM5A | |
| SCHEMBL23054209 | 0.73 | NOTUM (0.36) | ADORA2AADORA2BGPR119DGAT1 | |
| SCHEMBL22778802 | 0.73 | CNR2 (0.48) | — | |
| SCHEMBL12459121 | 0.70 | NOTUM (0.40) | ADORA2AADORA2BGPR119DGAT1 | |
| Cyanide SCHEMBL27956499 | 0.70 | DRD2 (0.44) | PDE10ADRD2DRD4DRD3KDM5A | |
| SCHEMBL19464707 | 0.69 | ALDH1A1 (0.32) | — | |
| SCHEMBL13141206 | 0.68 | NOTUM (0.36) | ADORA2AADORA2BGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | SLC40A1, HAMP, SLC19A1 | PDE10A 3407/4885DRD2 3875/4885DRD4 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.